Antitrust Concerns Don’t Cloud Merck-Schering Deal
This article was originally published in The Pink Sheet Daily
Merck and Schering expect limited divestments, including one of their two products in development for colorectal cancer.
You may also be interested in...
Merck’s acquisition of Schering-Plough brings much-needed late-stage assets, including potential blockbusters like TRA and bocepravir; the combined pipelines also strengthens existing footholds in neuroscience and respiratory drugs.
Pfizer aims to acquire rival Wyeth in a proposed deal valued at approximately $68 billion, broadening Pfizer's leadership position in the market by creating a drug powerhouse with combined sales of more than $71 billion, based on 2008 revenues
Pink Sheet reporter and editors examine the struggle over the FDA’s reputation, whether a coronavirus vaccine could be made available without sponsor cooperation, and the late Supreme Court Justice Ruth Bader Ginsburg’s legacy for pharma.